

# A living WHO guideline on drugs for covid-19

BMJ, The

370, m3379

DOI: [10.1136/bmj.m3379](https://doi.org/10.1136/bmj.m3379)

Citation Report

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies. <i>Journal of Evidence-Based Medicine</i> , 2020, 13, 255-260.	0.7	30
2	Clinical management of lung cancer patients during the outbreak of COVID-19 epidemic. <i>Infectious Agents and Cancer</i> , 2020, 15, 56.	1.2	5
3	Early management of critically ill patients with COVID-19. <i>Journal of the American College of Emergency Physicians Open</i> , 2020, 1, 1418-1426.	0.4	2
4	The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19. <i>Intensive Care Medicine</i> , 2020, 46, 2067-2070.	3.9	38
5	Increasing Age, the Existence of Comorbidities, and Corticosteroid Treatment in Combination With Antiviral Therapy Prolongs the Recovery of SARS-COV-2-Infected Patients, Measured as the Conversion From Positive to Negative rtPCR: A 239 Patients' Retrospective Study. <i>Frontiers in Medicine</i> , 2020, 7, 575439.	1.2	2
6	Covid -19, misinformation, and antimicrobial resistance. <i>BMJ, The</i> , 2020, 371, m4501.	3.0	22
7	Recommendations for the Diagnosis, Prevention, and Control of Coronavirus Disease-19 in Children—The Chinese Perspectives. <i>Frontiers in Pediatrics</i> , 2020, 8, 553394.	0.9	26
8	Management of Pediatric Kidney Transplant Patients During the COVID-19 Pandemic: Guidance From the Canadian Society of Transplantation Pediatric Group. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812096784.	0.6	17
9	Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis. <i>Tropical Medicine and Infectious Disease</i> , 2020, 5, 180.	0.9	34
10	Remdesivir: a pendulum in a pandemic. <i>BMJ, The</i> , 2020, 371, m4560.	3.0	4
11	Covid-19: The lost lessons of Tamiflu. <i>BMJ, The</i> , 2020, , m4701.	3.0	5
12	Developing Guidelines Before, During, and After the COVID-19 Pandemic. <i>Annals of Internal Medicine</i> , 2020, 173, 1012-1014.	2.0	18
13	Drug treatments for covid-19: living systematic review and network meta-analysis. <i>BMJ, The</i> , 2020, 370, m2980.	3.0	592
14	Producing and using timely comparative evidence on drugs: lessons from clinical trials for covid-19. <i>BMJ, The</i> , 2020, 371, m3869.	3.0	16
15	Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 1170-1172.	5.2	98
16	Covid-19: We need to understand the risks to tackle them. <i>BMJ, The</i> , 2020, , m3790.	3.0	1
17	Can Natural Polyphenols Help in Reducing Cytokine Storm in COVID-19 Patients?. <i>Molecules</i> , 2020, 25, 5888.	1.7	25
18	Predicting outcomes in COVID-19: From internal validation to improving care. <i>EBioMedicine</i> , 2020, 61, 103090.	2.7	0

#	ARTICLE	IF	CITATIONS
19	Covid-19: EU countries spent over â,~220m stockpiling remdesivir despite lack of effectiveness, finds investigation. <i>BMJ, The</i> , 2020, 371, m4749.	3.0	3
20	Pharmacological principles guiding prolonged glucocorticoid treatment in ARDS. <i>Intensive Care Medicine</i> , 2020, 46, 2284-2296.	3.9	79
21	Sepsis in the critically ill patient: current and emerging management strategies. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 635-647.	2.0	12
22	Dexamethasone in Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 693-704.	13.9	8,063
23	Weekly updates of national living evidence-based guidelines: methods for the Australian living guidelines for care of people with COVID-19. <i>Journal of Clinical Epidemiology</i> , 2021, 131, 11-21.	2.4	50
24	Corticosteroids for Patients With Coronavirus Disease 2019 (COVID-19) With Different Disease Severity: A Meta-Analysis of Randomized Clinical Trials. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021, 35, 578-584.	0.6	73
25	SARS-CoV-2: Targeted managements and vaccine development. <i>Cytokine and Growth Factor Reviews</i> , 2021, 58, 16-29.	3.2	44
26	Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study. <i>International Journal of Infectious Diseases</i> , 2021, 103, 288-296.	1.5	66
27	COVIDâ€19 vaccines: one step towards the beginning of the end of the global impact of the pandemic. <i>Anaesthesia</i> , 2021, 76, 435-443.	1.8	4
28	Integrating research into clinical practice: challenges and solutions for Canada. <i>Cmaj</i> , 2021, 193, E127-E131.	0.9	24
29	Severe COVID-19 Infectionsâ€”Knowledge Gained and Remaining Questions. <i>JAMA Internal Medicine</i> , 2021, 181, 9.	2.6	15
30	Acyclovir As a Potential Add-On Treatment for COVID-19; A Narrative Review. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
32	COVID-19 and Sepsis. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 3301-3311.	0.4	37
33	Viral infections in lung transplantation. <i>Journal of Thoracic Disease</i> , 2021, 13, 6673-6694.	0.6	9
34	SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. <i>The Cochrane Library</i> , 0, , .	1.5	16
35	The emergence of post-COVID-19 mucormycosis in India: Can we prevent it?. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 1645.	0.5	21
36	Secondary organizing pneumonia after coronavirus disease 2019: Two cases. <i>Respiratory Medicine Case Reports</i> , 2021, 32, 101356.	0.2	12
37	Severe warm autoimmune hemolytic anemia in COVID-19 managed with least incompatible RBC product and glucocorticoids. <i>Annals of Hematology</i> , 2022, 101, 431-432.	0.8	6

#	ARTICLE	IF	CITATIONS
38	Macrophage Migration Inhibitory Factor (MIF) Plasma Concentration in Critically Ill COVID-19 Patients: A Prospective Observational Study. <i>Diagnostics</i> , 2021, 11, 332.	1.3	19
39	Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis. <i>F1000Research</i> , 2021, 10, 64.	0.8	5
40	Remdesivir for COVID-19 in Europe: will it provide value for money?. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 127-128.	5.2	14
41	Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities. <i>Pharmaceutics</i> , 2021, 13, 302.	2.0	24
42	Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2. <i>Frontiers in Oncology</i> , 2021, 11, 625707.	1.3	7
44	Efficacy and safety outcomes with remdesivir in COVID-19 patients: A meta-analysis. <i>World Journal of Meta-analysis</i> , 2021, 9, 74-87.	0.1	1
45	Higher vs Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia (COVID STEROID) Tj ETQq0 0 0 rgBT /Overlo 702-710.	0.7	13
46	Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH). <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1127-1141.	0.9	9
47	Efficacy and safety of systematic corticosteroids among severe COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 83.	7.1	57
49	COVID-19: Rethinking the Lockdown Groupthink. <i>Frontiers in Public Health</i> , 2021, 9, 625778.	1.3	80
50	Gestione del Covid-19 in etÀ pediatrica: documento di consenso. <i>Medico E Bambino</i> , 2021, 40, 85-101.	0.1	5
51	Balancing Healthcare and Economy Amidst the COVID-19 Pandemic: An Indian Experience. <i>Risk Management and Healthcare Policy</i> , 2021, Volume 14, 827-833.	1.2	6
53	Expert consensus statements for the management of COVID-19-related acute respiratory failure using a Delphi method. <i>Critical Care</i> , 2021, 25, 106.	2.5	121
54	Remdesivir. <i>Hospital Pharmacy</i> , 2023, 58, 420-430.	0.4	3
55	Are nucleotide inhibitors, already used for treating hepatitis C virus infection, a potential option for the treatment of COVID-19 compared with standard of care? A literature review. <i>World Journal of Virology</i> , 2021, 10, 53-61.	1.3	0
56	Tocilizumab administration in COVID-19 patients: Water on the fire or gasoline?. <i>Medical Mycology Case Reports</i> , 2021, 31, 32-34.	0.7	14
57	Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis. <i>F1000Research</i> , 0, 10, 64.	0.8	2
59	Skeletal Muscle Wasting and Function Impairment in Intensive Care Patients With Severe COVID-19. <i>Frontiers in Physiology</i> , 2021, 12, 640973.	1.3	58

#	ARTICLE	IF	CITATIONS
60	Real-life use of remdesivir in hospitalized patients with COVID-19. <i>Revista Espanola De Quimioterapia</i> , 2021, 34, 136-140.	0.5	20
61	SARS-CoV-2 and pediatric solid organ transplantation: Current knowns and unknowns. <i>Pediatric Transplantation</i> , 2021, 25, e13986.	0.5	6
62	A living WHO guideline on drugs to prevent covid-19. <i>BMJ, The</i> , 2021, 372, n526.	3.0	73
64	Impact of pathogen reduction methods on immunological properties of the COVID-19 convalescent plasma. <i>Vox Sanguinis</i> , 2021, 116, 665-672.	0.7	13
65	Cytopathology of bronchoalveolar lavages in COVID-19 pneumonia: A pilot study. <i>Cancer Cytopathology</i> , 2021, 129, 632-641.	1.4	10
67	COVID-19 in Children: Respiratory Involvement and Some Differences With the Adults. <i>Frontiers in Pediatrics</i> , 2021, 9, 622240.	0.9	15
68	A Community-Based Model to the COVID-19 Humanitarian Crisis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 639579.	1.8	8
70	COVID-19: immunopathology, pathophysiological mechanisms, and treatment options. <i>Journal of Pathology</i> , 2021, 254, 307-331.	2.1	86
71	Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT). <i>Clinical Microbiology and Infection</i> , 2021, 27, 389-395.	2.8	37
72	Second wave of the COVID-19 pandemic: D-dimer levels are not so high anymore. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 779-781.	1.0	1
73	Absence of "Cytokine Storm" in Hospitalized COVID-19 Patients: A Retrospective Cohort Study. <i>Infectious Disease Reports</i> , 2021, 13, 377-387.	1.5	3
74	Epidemiological and clinical characteristics of 65 hospitalized patients with COVID-19 in Liaoning, China. <i>World Journal of Clinical Cases</i> , 2021, 9, 2205-2217.	0.3	3
75	Prophylaxis against covid-19: living systematic review and network meta-analysis. <i>BMJ, The</i> , 2021, 373, n949.	3.0	78
76	Guidelines should not pool evidence from uncomplicated and severe COVID-19. <i>Lancet, The</i> , 2021, 397, 1262-1263.	6.3	11
77	Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 561-571.	1.3	10
79	Acceptance and attitudes toward COVID-19 vaccines: A cross-sectional study from Jordan. <i>PLoS ONE</i> , 2021, 16, e0250555.	1.1	304
80	Ivermectin for preventing and treating COVID-19. <i>The Cochrane Library</i> , 0, , .	1.5	25
81	Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis. <i>European Journal of Pharmacology</i> , 2021, 897, 173926.	1.7	82

#	ARTICLE	IF	CITATIONS
82	IL-6 modulation for COVID-19: the right patients at the right time?. , 2021, 9, e002285.		32
83	Quality and consistency of clinical practice guidelines for treating children with COVID-19. Annals of Translational Medicine, 2021, 9, 633-633.	0.7	9
84	Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis. Intensive Care Medicine, 2021, 47, 521-537.	3.9	148
85	Attenuating the Effects of Novel COVID-19 (SARS-CoV-2) Infection-Induced Cytokine Storm and the Implications. Journal of Inflammation Research, 2021, Volume 14, 1487-1510.	1.6	50
86	We need clinical guidelines fit for a pandemic. BMJ, The, 2021, 373, n1093.	3.0	8
87	COVID-19 Management in the Pediatric Age: Consensus Document of the COVID-19 Working Group in Paediatrics of the Emilia-Romagna Region (RE-CO-Ped), Italy. International Journal of Environmental Research and Public Health, 2021, 18, 3919.	1.2	25
88	A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials. PLoS Medicine, 2021, 18, e1003629.	3.9	21
89	COVID-19: breaking down a global health crisis. Annals of Clinical Microbiology and Antimicrobials, 2021, 20, 35.	1.7	175
90	Drug repurposing of dermatologic medications to treat coronavirus disease 2019: Science or fiction?. Clinics in Dermatology, 2021, 39, 430-445.	0.8	2
91	Questioning Tocilizumab Use in Hospitalized Patients With Coronavirus Disease 2019. Chest, 2021, 159, 2115-2116.	0.4	0
92	Covid-19: Why we must temper urgency with diligence. BMJ, The, 0, , n1210.	3.0	0
93	Existing Drugs Considered as Promising in COVID-19 Therapy. International Journal of Molecular Sciences, 2021, 22, 5434.	1.8	24
94	Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study. Nutrients, 2021, 13, 1760.	1.7	71
95	Drug Repurposing for the Treatment of COVID-19: A Knowledge Graph Approach. Advanced Therapeutics, 2021, 4, 2100055.	1.6	12
96	The second wave of desaturation in coronavirus disease 2019. New Microbes and New Infections, 2021, 41, 100866.	0.8	1
97	Immunosuppression and Clostridioides (Clostridium) difficile Infection Risk in Metabolic and Bariatric Surgery Patients. Journal of the American College of Surgeons, 2021, 233, 223-231.	0.2	5
98	Insights into SARS-CoV-2 Persistence and Its Relevance. Viruses, 2021, 13, 1025.	1.5	37
99	SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. The Cochrane Library, 0, , .	1.5	2

#	ARTICLE	IF	CITATIONS
100	Keeping a Balance During the Pandemic: a Narrative Review on the Important Role of Micronutrients in Preventing Infection and Reducing Complications of COVID-19. <i>Current Nutrition Reports</i> , 2021, 10, 200-210.	2.1	9
102	Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study. <i>BMJ, The</i> , 2021, 373, n1038.	3.0	50
103	Vitamin D supplementation for the treatment of COVID-19: a living systematic review. <i>The Cochrane Library</i> , 2021, 2021, CD015043.	1.5	78
104	Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, e102-e109.	1.7	22
105	Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2021, 24, 277-291.	0.9	16
107	COVID-19 chemoprevention. <i>International Journal of Infectious Diseases</i> , 2021, 107, 31-33.	1.5	0
108	Pericardial Diseases in COVID19: a Contemporary Review. <i>Current Cardiology Reports</i> , 2021, 23, 90.	1.3	40
109	The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2). <i>BioMed Research International</i> , 2021, 2021, 1-20.	0.9	13
111	Unbiased Analysis of Temporal Changes in Immune Serum Markers in Acute COVID-19 Infection With Emphasis on Organ Failure, Anti-Viral Treatment, and Demographic Characteristics. <i>Frontiers in Immunology</i> , 2021, 12, 650465.	2.2	19
112	COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 705-715.	8.2	26
113	Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021. <i>Frontiers in Pharmacology</i> , 2021, 12, 659577.	1.6	31
114	Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis. <i>F1000Research</i> , 2021, 10, 64.	0.8	7
115	Anti-fibrotic Treatment for Pulmonary Fibrosis Induced by COVID-19: A Case Presentation. <i>Turkish Journal of Anaesthesiology and Reanimation</i> , 2022, 50, 228-231.	0.2	2
117	Cardiac Events Potentially Associated to Remdesivir: An Analysis from the European Spontaneous Adverse Event Reporting System. <i>Pharmaceuticals</i> , 2021, 14, 611.	1.7	28
118	Urgent needs to accelerate the race for COVID-19 therapeutics. <i>EClinicalMedicine</i> , 2021, 36, 100911.	3.2	7
119	SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care. <i>Nature Communications</i> , 2021, 12, 3406.	5.8	122
120	Glucocorticoid-Glucocorticoid Receptor Response to Severe Acute Respiratory Syndrome Coronavirus 2. <i>Critical Care Medicine</i> , 2021, Publish Ahead of Print, 2157-2160.	0.4	1
121	Drug-induced liver injury associated with lopinavir-ritonavir in patients with COVID-19: a disproportionality analysis of U.S. food and drug administration adverse event reporting system (FAERS) data. <i>International Journal of Clinical Pharmacy</i> , 2021, 43, 1116-1122.	1.0	10

#	ARTICLE	IF	CITATIONS
122	Therapeutic antibodies under development for SARS-CoV-2. <i>View</i> , 2021, , 20200178.	2.7	4
124	Cellular Uptake and Intracellular Phosphorylation of GS-441524: Implications for Its Effectiveness against COVID-19. <i>Viruses</i> , 2021, 13, 1369.	1.5	12
125	Acute Fulminant Mucormycosis Triggered by Covid 19 Infection in a Young Patient. <i>Indian Journal of Otolaryngology and Head and Neck Surgery</i> , 2022, 74, 3442-3446.	0.3	14
128	Potential impact of intervention strategies on COVID-19 transmission in Malawi: a mathematical modelling study. <i>BMJ Open</i> , 2021, 11, e045196.	0.8	8
129	Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia. <i>New England Journal of Medicine</i> , 2021, 385, 406-415.	13.9	342
130	Acyclovir as a Potential Adjuvant Therapy in COVID-19 Treatment Regimens. <i>Pharmaceutical Sciences</i> , 2021, , .	0.1	6
131	Ivermectin for preventing and treating COVID-19. <i>The Cochrane Library</i> , 2021, 2021, CD015017.	1.5	101
132	The Second Wave of COVID-19: Clinical Pharmacy Services During a Field Hospital Operation. <i>Hospital Pharmacy</i> , 2022, 57, 205-210.	0.4	2
133	Contemporary narrative review of treatment options for COVID-19. <i>Respirology</i> , 2021, 26, 745-767.	1.3	12
134	Impacts of diabetes mellitus on clinical and para-clinical parameters among COVID-19 patients. <i>Journal of Diabetes and Metabolic Disorders</i> , 2021, , 1-9.	0.8	1
135	Covid-19: The UK's political gamble that bodes ill for health and the health service. <i>BMJ</i> , The, 0, , n1848.	3.0	4
137	Choosing Wisely for COVID-19: ten evidence-based recommendations for patients and physicians. <i>Nature Medicine</i> , 2021, 27, 1324-1327.	15.2	12
138	Cold agglutinin disease and COVID-19 requiring therapeutic plasma exchange. <i>BMJ Case Reports</i> , 2021, 14, e244227.	0.2	4
139	A cost of illness study of COVID-19 patients and retrospective modelling of potential cost savings when administering remdesivir during the pandemic "first wave" in a German tertiary care hospital. <i>Infection</i> , 2022, 50, 191-201.	2.3	8
141	Intravenous methylprednisolone with or without tocilizumab in patients with severe COVID-19 pneumonia requiring oxygen support: A prospective comparison. <i>Journal of Infection and Public Health</i> , 2021, 14, 985-989.	1.9	25
142	The Evolution of Clinical Knowledge During COVID-19: Towards a Global Learning Health System. <i>Yearbook of Medical Informatics</i> , 2021, 30, 176-184.	0.8	7
143	COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome. <i>Leukemia and Lymphoma</i> , 2021, 62, 3384-3393.	0.6	25
144	Theory and reality of antivirals against SARS-CoV-2. <i>World Journal of Clinical Cases</i> , 2021, 9, 6663-6673.	0.3	1



#	ARTICLE	IF	CITATIONS
145	Tailoring glucocorticoids in patients with severe COVID-19: a narrative review. <i>Annals of Translational Medicine</i> , 2021, 9, 1261-1261.	0.7	3
146	Caution When Comparing the Impact of Corticosteroids in COVID-19. <i>Chest</i> , 2021, 160, e243-e244.	0.4	1
147	Interventions for palliative symptom control in COVID-19 patients. <i>The Cochrane Library</i> , 2021, 2021, CD015061.	1.5	8
148	Current COVID-19 vaccine trials in high-income countries: are placebo-controlled trials ethical?. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1565-1567.	2.8	11
149	An Overview of the Pathogenesis, Transmission, Diagnosis, and Management of Endemic Human Coronaviruses: A Reflection on the Past and Present Episodes and Possible Future Outbreaks. <i>Pathogens</i> , 2021, 10, 1108.	1.2	14
150	A metaresearch study revealed susceptibility of Covid-19 treatment research to white hat bias: first, do no harm. <i>Journal of Clinical Epidemiology</i> , 2021, 136, 55-63.	2.4	9
151	Surveillance and care for confirmed and suspected patients with COVID-19 in general practice (CovidCare): study protocol for an observational trial. <i>BMC Family Practice</i> , 2021, 22, 173.	2.9	2
152	Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA). <i>Cardiovascular Research</i> , 2021, 117, 2705-2729.	1.8	95
153	SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. <i>The Cochrane Library</i> , 2021, 2021, CD013825.	1.5	114
155	Mechanistic Insights into the Inhibition of SARS-CoV-2 Main Protease by Clovamide and Its Derivatives: In Silico Studies. <i>Biophysica</i> , 2021, 1, 377-404.	0.6	6
156	Severe COVID-19 in Uganda across Two Epidemic Phases: A Prospective Cohort Study. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 105, 740-744.	0.6	10
157	Mortality Variations of COVID-19 from Different Hospital Settings During Different Pandemic Phases: A Multicenter Retrospective Study. <i>Western Journal of Emergency Medicine</i> , 2021, 22, 1051-1059.	0.6	1
158	Renal and Hepatic Toxicity Analysis of Remdesivir Formulations: Does What Is on the Inside Really Count?. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0104521.	1.4	6
159	Management of acute kidney injury associated with Covid-19. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, Publish Ahead of Print, 563-570.	1.0	3
160	Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. <i>BMJ</i> , The, 2021, 374, n2231.	3.0	59
161	Emergency drug use in a pandemic: Harsh lessons from COVID-19. <i>Cell</i> , 2021, 184, 5497-5500.	13.5	2
162	Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19. <i>Annals of Internal Medicine</i> , 2021, 174, 1261-1269.	2.0	84
163	Nutritional Immunity, Zinc Sufficiency, and COVID-19 Mortality in Socially Similar European Populations. <i>Frontiers in Immunology</i> , 2021, 12, 699389.	2.2	16

#	ARTICLE	IF	CITATIONS
164	Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of Systematic Reviews. <i>Diagnostics</i> , 2021, 11, 1663.	1.3	19
165	Repurposing clinically approved drugs for COVID-19 treatment targeting SARS-CoV-2 papain-like protease. <i>International Journal of Biological Macromolecules</i> , 2021, 188, 137-146.	3.6	32
166	Clinical trials in COVID-19 management & prevention: A meta-epidemiological study examining methodological quality. <i>Journal of Clinical Epidemiology</i> , 2021, 139, 68-79.	2.4	11
167	Recommendations on Inpatient Treatment of Patients With COVID-19. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2021, 118, .	0.6	35
168	Pandemics Throughout History. <i>Frontiers in Microbiology</i> , 2020, 11, 631736.	1.5	330
169	Acute severe respiratory syndrome coronavirus-2 treatment overview for pediatrics. <i>Current Opinion in Pediatrics</i> , 2021, Publish Ahead of Print, 129-135.	1.0	3
170	Potential Interaction Between SARS-CoV-2 and Thyroid: A Review. <i>Endocrinology</i> , 2021, 162, .	1.4	77
171	Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. <i>BMJ, The</i> , 2021, 372, n84.	3.0	309
172	Making Sense of Contradictory Evidence in Coronavirus Disease 2019 Trials. <i>Clinical Infectious Diseases</i> , 2021, , .	2.9	1
173	Broad guidelines for primary care practitioners/standalone private health facilities/frontline healthcare facilities in view of COVID-19 pandemic. <i>Journal of Family Medicine and Primary Care</i> , 2021, 10, 1.	0.3	5
174	Anesthetic Management of a Child With Propionic Acidemia Complicated by Bacteremia and Severe Acute Respiratory Syndrome Coronavirus 2. <i>Journal of Medical Cases</i> , 2021, 12, 152-156.	0.4	2
175	Multidimensional Evaluation of All-Cause Mortality Risk and Survival Analysis for Hospitalized Patients with COVID-19. <i>International Journal of Medical Sciences</i> , 2021, 18, 3140-3149.	1.1	6
176	Potential SARS-CoV-2 3CLpro inhibitors from chromene, flavonoid and hydroxamic acid compound based on FRET assay, docking and pharmacophore studies. <i>Results in Chemistry</i> , 2021, 3, 100195.	0.9	15
179	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 4673-4695.	1.1	43
180	Multisystem Inflammatory Syndrome in Children (MIS-C), a Post-viral Myocarditis and Systemic Vasculitisâ€”A Critical Review of Its Pathogenesis and Treatment. <i>Frontiers in Pediatrics</i> , 2020, 8, 626182.	0.9	120
181	The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9775.	1.8	40
182	COVID-19 treatment : a growing (anti)body of evidence. <i>South African General Practitioner</i> , 2020, 1, 172-174.	0.0	2
183	Pragmatic Recommendations for Therapeutics of Hospitalized COVID-19 Patients in Low- and Middle-Income Countries. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, , .	0.6	3

#	ARTICLE	IF	CITATIONS
184	Implications for clinical dental practice during the coronavirus disease pandemic: A scoping review. <i>Journal of Prosthodontic Research</i> , 2022, 66, 6-11.	1.1	4
185	The Saudi Critical Care Society practice guidelines on the management of COVID-19 in the ICU: Therapy section. <i>Journal of Infection and Public Health</i> , 2022, 15, 142-151.	1.9	10
186	The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?. <i>Intensive Care Medicine</i> , 2021, 47, 1315-1318.	3.9	6
187	Clinical characteristics and outcomes of critically ill mechanically ventilated COVID-19 patients receiving interleukin-6 receptor antagonists and corticosteroid therapy: a preliminary report from a multinational registry. <i>European Journal of Medical Research</i> , 2021, 26, 117.	0.9	18
188	Longitudinal urinary biomarkers of immunological activation in covid-19 patients without clinically apparent kidney disease versus acute and chronic failure. <i>Scientific Reports</i> , 2021, 11, 19675.	1.6	5
189	Integrating Chinese and western medicine for COVID-19: A living evidence-based guideline (version 1). <i>Journal of Evidence-Based Medicine</i> , 2021, 14, 313-332.	0.7	21
190	Pathogenesis, Symptomatology, and Transmission of SARS-CoV-2 through Analysis of Viral Genomics and Structure. <i>MSystems</i> , 2021, 6, e0009521.	1.7	26
191	Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1690.	3.8	169
192	Convalescent Plasma for Patients Hospitalized With Coronavirus Disease 2019: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials. <i>Transfusion Medicine Reviews</i> , 2022, 36, 16-26.	0.9	11
193	Micronutrients for potential therapeutic use against COVID-19; a review. <i>Clinical Nutrition ESPEN</i> , 2021, 46, 9-13.	0.5	5
194	Potential interactions between antineoplastic agents and medicines used to treat Covid-19. <i>Journal of Oncology Pharmacy Practice</i> , 2021, , 107815522110404.	0.5	2
195	Covid-19: Fatal errors, not fatalism, created UK's public health disaster. <i>BMJ</i> , The, 0, , n2497.	3.0	2
196	Complications of Critical COVID-19. <i>Chest</i> , 2022, 161, 989-998.	0.4	14
197	Antibiotics for the treatment of COVID-19. <i>The Cochrane Library</i> , 2022, 2022, CD015025.	1.5	49
198	Real-Life Impact of Glucocorticoid Treatment in COVID-19 Mortality: A Multicenter Retrospective Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4678.	1.0	3
199	Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. <i>Intensive Care Medicine</i> , 2021, 47, 1258-1270.	3.9	88
200	COVID-19 Advanced Care. <i>Journal of Personalized Medicine</i> , 2021, 11, 1082.	1.1	1
201	Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1807.	3.8	174

#	ARTICLE	IF	CITATIONS
202	Moxidectin and Ivermectin Inhibit SARS-CoV-2 Replication in Vero E6 Cells but Not in Human Primary Bronchial Epithelial Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0154321.	1.4	19
203	A novel device for treatment of osteonecrosis of femoral head: Feasibility and preliminary efficacy of animal study. <i>Journal of Orthopaedic Translation</i> , 2021, 31, 20-25.	1.9	7
204	SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies. <i>International Immunopharmacology</i> , 2021, 101, 108232.	1.7	14
205	Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data. <i>Infectious Diseases and Therapy</i> , 2021, , 1.	1.8	6
206	The Role of Glucocorticoids in Inflammatory Diseases. <i>Cells</i> , 2021, 10, 2921.	1.8	44
207	Efficacy and safety of tocilizumab versus standard care/placebo in patients with COVID-19; a systematic review and meta-analysis of randomized clinical trials. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1955-1963.	1.1	22
208	Fulminant necrotising amoebic colitis after corticosteroid therapy for severe COVID-19. <i>BMJ Case Reports</i> , 2021, 14, e246110.	0.2	2
209	Expert Consensus Statements on the Use of Corticosteroids in Non-severe COVID-19. <i>Indian Journal of Critical Care Medicine</i> , 2021, 25, 1280-1285.	0.3	5
210	Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines. <i>Molecular Biomedicine</i> , 2020, 1, 16.	1.7	4
211	COVID-19 Treatment at a Glance. <i>Turkish Thoracic Journal</i> , 2020, 21, 438-445.	0.2	2
212	COVID-19 in Lombardy seven months later: what we learned and modified in patients' management. <i>Minerva Anestesiologica</i> , 2020, 86, 1353-1354.	0.6	1
213	Vitamin D Endocrine System and COVID-19. <i>JBMR Plus</i> , 2021, 5, e10576.	1.3	13
214	Identification and Development of Therapeutics for COVID-19. <i>MSystems</i> , 2021, 6, e0023321.	1.7	20
219	Differences in mortality in critically ill elderly patients during the second COVID-19 surge in Europe. <i>Critical Care</i> , 2021, 25, 344.	2.5	7
220	Treatment and therapeutic agents. , 2022, , 121-176.		0
221	Awareness, value and use of the Australian living guidelines for the clinical care of people with COVID-19: an impact evaluation. <i>Journal of Clinical Epidemiology</i> , 2022, 143, 11-21.	2.4	10
222	COVID-19, the Pandemic of the Century and Its Impact on Cardiovascular Diseases. <i>Cardiology Discovery</i> , 2021, 1, 233-258.	0.6	6
224	The Organic Turn: Coping With Pandemic and Non-pandemic Challenges by Integrating Evidence-, Theory-, Experience-, and Context-Based Knowledge in Advising Health Policy. <i>Frontiers in Public Health</i> , 2021, 9, 727427.	1.3	12

#	ARTICLE	IF	CITATIONS
225	Fragility Index and Fragility Quotient in Randomized Controlled Trials on Corticosteroids in ARDS Due to COVID-19 and Non-COVID-19 Etiology. <i>Journal of Clinical Medicine</i> , 2021, 10, 5287.	1.0	7
226	COVID-19 in Children. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 1-14.	1.9	10
227	A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues. <i>Vaccines</i> , 2021, 9, 1387.	2.1	51
229	Intermediate-to-therapeutic versus prophylactic anticoagulation for coagulopathy in hospitalized COVID-19 patients: a systemic review and meta-analysis. <i>Thrombosis Journal</i> , 2021, 19, 91.	0.9	12
230	Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies. <i>Inflammation Research</i> , 2022, 71, 39-56.	1.6	23
231	Ten months of temporal variation in the clinical journey of hospitalised patients with COVID-19: An observational cohort. <i>ELife</i> , 2021, 10, .	2.8	9
232	Guidelines developed under pressure. The case of the COVID-19 low-quality "rapid" guidelines and potential solutions. <i>Journal of Clinical Epidemiology</i> , 2022, 142, 194-199.	2.4	10
233	COVID-19 and Rheumatoid Arthritis Crosstalk: Emerging Association, Therapeutic Options and Challenges. <i>Cells</i> , 2021, 10, 3291.	1.8	38
234	Anakinra in COVID-19: A step closer to the cure. <i>European Journal of Internal Medicine</i> , 2022, 96, 113-114.	1.0	5
235	Dexamethasone 12Âmg versus 6Âmg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. <i>Intensive Care Medicine</i> , 2022, 48, 45-55.	3.9	70
236	Clinical outcomes of corticosteroids for COVID-19 patients at the National Center for Global Health and Medicine during the first wave of infections. <i>Respiratory Investigation</i> , 2021, , .	0.9	0
237	A Pro-Inflammatory Gut Microbiome Characterizes SARS-CoV-2 Infected Patients and a Reduction in the Connectivity of an Anti-Inflammatory Bacterial Network Associates With Severe COVID-19. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 747816.	1.8	51
238	Forced association of SARS-CoV-2 proteins with the yeast proteome perturb vesicle trafficking. <i>Microbial Cell</i> , 2021, 8, 280-296.	1.4	3
239	Potential kidney damage associated with the use of remdesivir for COVID-19: analysis of a pharmacovigilance database. <i>Cadernos De Saude Publica</i> , 2021, 37, e00077721.	0.4	13
240	Cytokine Storm, Corticosteroids and Înterleukin-6 Receptor Antibodies in Context of Antiinflammatory Treatment in COVID-19. <i>Journal of Pharmaceutical Research International</i> , 0, , 67-75.	1.0	2
241	Impact of COVID-19 in hematopoietic stem cell transplant recipients: A systematic review and meta-analysis. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	28
242	Outside any therapeutic trial prescription of hydroxychloroquine for hospitalized patients with covid-19 during the first wave of the pandemic: A national inquiry of prescription patterns among French hospitalists. <i>PLoS ONE</i> , 2022, 17, e0261843.	1.1	2
243	Covid-19: WHO recommends baricitinib and sotrovimab to treat patients. <i>BMJ, The</i> , 2022, 376, o97.	3.0	19

#	ARTICLE	IF	CITATIONS
244	Effects of the COVID-19 pandemic on head lice and scabies infestation dynamics: a population-based study in France. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 867-872.	0.6	10
245	COVID-19 IN CHILDREN AND ADOLESCENT: CHARACTERISTICS AND SPECIFICITIES IN IMMUNOCOMPETENT AND ONCOHEMATOLOGICAL PATIENTS. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2022, 14, e2022009.	0.5	5
246	Understanding the activating mechanism of the immune system against COVID-19 by Traditional Indian Medicine: Network pharmacology approach. <i>Advances in Protein Chemistry and Structural Biology</i> , 2022, 129, 275-379.	1.0	7
248	Efficacy of remdesivir for hospitalized COVID-19 patients with end stage renal disease. <i>World Journal of Critical Care Medicine</i> , 2022, 11, 48-57.	0.8	2
249	High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106516.	1.1	32
250	Defining Optimal Respiratory Support for Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 531.	3.8	7
251	Risk Factors for Therapeutic Intervention of Remdesivir in Mild to Moderate COVID-19—A Single-Center Retrospective Study of the COVID-19 Fourth Pandemic Period in Wakayama, Japan. <i>Medicina (Lithuania)</i> , 2022, 58, 118.	0.8	3
252	The Australian living guidelines for the clinical care of people with COVID-19: What worked, what didn't and why, a mixed methods process evaluation. <i>PLoS ONE</i> , 2022, 17, e0261479.	1.1	11
253	Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. <i>Cmaj</i> , 2022, 194, E242-E251.	0.9	103
254	Dealing with Corticosteroid and High-Dose Cyclosporine Therapy in a Pyoderma Gangrenosum Patient Contracting a COVID-19 Infection. <i>Journal of Personalized Medicine</i> , 2022, 12, 173.	1.1	2
256	Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score-matched retrospective cohort study. <i>International Immunopharmacology</i> , 2022, 106, 108570.	1.7	13
257	Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis. <i>Antiviral Research</i> , 2022, 198, 105247.	1.9	39
258	From hydroxychloroquine to ivermectin: how unproven "cures" can go viral. <i>Clinical Microbiology and Infection</i> , 2022, 28, 472-474.	2.8	9
259	Clinical update on COVID-19 for the emergency clinician: Presentation and evaluation. <i>American Journal of Emergency Medicine</i> , 2022, 54, 46-57.	0.7	146
260	An epidemic of iatrogenic Cushing's syndrome in anticipation in post-COVID era. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 412.	0.3	3
261	Impact of corticosteroid therapy on the survival of critical COVID-19 patients admitted into an intensive care unit. <i>Revista Española De Anestesiología Y Reanimación (English Edition)</i> , 2022, 69, 120-120.	0.1	0
262	Medical research needs a Sue Gray. <i>BMJ, The</i> , 0, , o274.	3.0	1
263	Convalescent plasma in hospitalized patients with COVID-19 pneumonia: a case-control prospective study. <i>Rivista Italiana Della Medicina Di Laboratorio</i> , 0, , .	0.2	0

#	ARTICLE	IF	CITATIONS
264	WHO covid-19 drugs guideline: reconsider using convalescent plasma. <i>BMJ, The</i> , 2022, 376, o295.	3.0	6
265	Community-Acquired Pneumonia in Canada During Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac043.	0.4	4
266	Re: ESCMID COVID-19 living guidelines: drug treatment and clinical management™ by Bartoletti et al. <i>Clinical Microbiology and Infection</i> , 2021, , .	2.8	3
267	In Silico Analysis of Inhibiting Papain-like Protease from SARS-CoV-2 by Using Plant-Derived Peptides. <i>International Journal of Peptide Research and Therapeutics</i> , 2022, 28, 24.	0.9	6
268	COVID-19 in Low- and Middle-Income Countries (LMICs): A Narrative Review from Prevention to Vaccination Strategy. <i>Vaccines</i> , 2021, 9, 1477.	2.1	25
271	Identifying factors contributing to increased susceptibility to COVID-19 risk: a systematic review of Mendelian randomization studies. <i>International Journal of Epidemiology</i> , 2022, 51, 1088-1105.	0.9	25
272	SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants. <i>Pathogens</i> , 2022, 11, 275.	1.2	9
273	A comprehensive review of adverse events to drugs used in COVID-19 patients: Recent clinical evidence. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13763.	1.7	5
274	Potentially effective drugs for the treatment of COVID-19 or MIS-C in children: a systematic review. <i>European Journal of Pediatrics</i> , 2022, 181, 2135-2146.	1.3	19
275	Use of tocilizumab and sarilumab alone or in combination with corticosteroids for covid-19: systematic review and network meta-analysis. , 2022, 1, e000036.		13
276	Adrenomedullin Therapy in Moderate to Severe COVID-19. <i>Biomedicines</i> , 2022, 10, 533.	1.4	8
277	Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies. <i>Frontiers in Pharmacology</i> , 2022, 13, 835136.	1.6	17
278	EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1628-1639.	0.5	89
279	Herd Behavior in Medicine: Examples From COVID-19. <i>Cureus</i> , 2022, 14, e22472.	0.2	0
280	Therapeutics and COVID-19™ A living WHO guideline: Endorsement by the Scandinavian Society of Anaesthesiology and Intensive Care Medicine. <i>Acta Anaesthesiologica Scandinavica</i> , 2022, , .	0.7	3
281	What's new on the management of obstetric patients who tested positive for Covid-19?. <i>Minerva Anestesiologica</i> , 2022, , .	0.6	0
282	Evaluation of Antimicrobial Drug Use and Concurrent Infections During Hospitalization of Patients With COVID-19 in Japan. <i>JAMA Network Open</i> , 2022, 5, e220040.	2.8	2
283	Review of Anti-inflammatory and Anti-viral therapeutics for hospitalized patients infected with SARS-CoV-2. <i>Critical Care Clinics</i> , 2022, , .	1.0	3

#	ARTICLE	IF	CITATIONS
284	Long-term outcomes of dexamethasone 12Âmg versus 6Âmg in patients with COVID-19 and severe hypoxaemia. <i>Intensive Care Medicine</i> , 2022, 48, 580-589.	3.9	17
285	Pulmonary Inflammatory Response in Lethal COVID-19 Reveals Potential Therapeutic Targets and Drugs in Phases III/IV Clinical Trials. <i>Frontiers in Pharmacology</i> , 2022, 13, 833174.	1.6	6
286	In Response to: Corticosteroids in Non-severe COVID-19: Finding Window of Opportunity. <i>Indian Journal of Critical Care Medicine</i> , 2022, 26, 405-405.	0.3	0
288	Climate, pandemic, and war: an uncontrolled multicrisis of existential proportions. <i>BMJ, The</i> , 0, , o689.	3.0	3
289	COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes. <i>Clinical Microbiology Reviews</i> , 2022, 35, e0020021.	5.7	64
290	Inflamaging at the Time of COVID-19. <i>Clinics in Geriatric Medicine</i> , 2022, 38, 473-481.	1.0	14
291	Molnupiravirâ€™s authorisation was premature. <i>BMJ, The</i> , 2022, 376, o443.	3.0	25
293	Seroconversion rates among different designs of COVID-19 vaccines: a network meta-analysis of randomized controlled trials. <i>F1000Research</i> , 0, 11, 299.	0.8	0
294	Corticosteroids for Non-severe COVID-19: Primum Non Nocere. <i>Indian Journal of Critical Care Medicine</i> , 2022, 26, 403-404.	0.3	2
296	Association of high SARS-CoV-2 RNAemia with diabetes and mortality in critically ill COVID-19 patients. <i>IScience</i> , 2022, 25, 104075.	1.9	5
297	Fluvoxamine in Nonhospitalized Patients With Acute COVID-19 Infection and the Lack of Efficacy in Reducing Rates of Hospitalization, Mechanical Ventilation, and Mortality in Placebo-Controlled Trials: A Systematic Review and Meta-Analysis. <i>American Journal of Therapeutics</i> , 2022, 29, e298-e304.	0.5	9
298	Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. <i>Nature Medicine</i> , 2022, 28, 1297-1302.	15.2	235
299	Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials. <i>BMJ Open</i> , 2022, 12, e048502.	0.8	28
301	Guidelines and evidence-based recommendations in anaesthesia: where do we stand?. <i>British Journal of Anaesthesia</i> , 2022, , .	1.5	5
302	Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis. <i>Antiviral Research</i> , 2022, 200, 105270.	1.9	14
303	Corticosteroid therapy in COVID-19 associated with in-hospital mortality in geriatric patients: a propensity matched cohort study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2022, , .	1.7	7
304	Liushen Capsules, a promising clinical candidate for COVID-19, alleviates SARS-CoV-2-induced pulmonary in vivo and inhibits the proliferation of the variant virus strains in vitro. <i>Chinese Medicine</i> , 2022, 17, 40.	1.6	8
305	Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India. <i>Lancet Infectious Diseases, The</i> , 2022, 22, e240-e253.	4.6	41



#	ARTICLE	IF	CITATIONS
306	Report from the CVOT Summit 2021: new cardiovascular, renal, and glyceimic outcomes. <i>Cardiovascular Diabetology</i> , 2022, 21, 50.	2.7	8
307	Host Defence Peptides: A Potent Alternative to Combat Antimicrobial Resistance in the Era of the COVID-19 Pandemic. <i>Antibiotics</i> , 2022, 11, 475.	1.5	10
308	Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020â€“Sep 2020; Sep 2020â€“May 2021) in the Veneto Oncology Network: The ROVID study. <i>European Journal of Cancer</i> , 2022, 167, 81-91.	1.3	3
309	Clinical update on COVID-19 for the emergency and critical care clinician: Medical management. <i>American Journal of Emergency Medicine</i> , 2022, 56, 158-170.	0.7	13
310	Comparing efficacy and safety of tocilizumab and methylprednisolone in the treatment of patients with severe COVID-19. <i>International Immunopharmacology</i> , 2022, 107, 108689.	1.7	2
311	Mortality Predictors in Severe COVID-19 Patients from an East European Tertiary Center: A Never-Ending Challenge for a No Happy Ending Pandemic. <i>Journal of Clinical Medicine</i> , 2022, 11, 58.	1.0	15
312	The association between therapeutic plasma exchange and the risk of mortality among patients critically ill with COVID-19: a meta-analysis. <i>F1000Research</i> , 2021, 10, 1280.	0.8	4
313	Investigation of the Molecular Mechanism of Coagulopathy in Severe and Critical Patients With COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 762782.	2.2	4
314	High Fasting Blood Glucose Level With Unknown Prior History of Diabetes Is Associated With High Risk of Severe Adverse COVID-19 Outcome. <i>Frontiers in Endocrinology</i> , 2021, 12, 791476.	1.5	9
315	The European clinical research response to optimise treatment of patients with COVID-19: lessons learned, future perspective, and recommendations. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e153-e158.	4.6	22
316	Ribavirin Treatment for Critically Ill COVID-19 Patients: An Observational Study. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 5287-5291.	1.1	9
317	Antirheumatic Drugs against COVID-19 from the Perspective of Rheumatologists. <i>Pharmaceuticals</i> , 2021, 14, 1256.	1.7	10
318	Adherence of Clinical Practice Guidelines for Pharmacologic Treatments of Hospitalized Patients With COVID-19 to Trustworthy Standards. <i>JAMA Network Open</i> , 2021, 4, e2136263.	2.8	5
319	Differences in mortality in critically ill elderly patients during the second COVID-19 surge in Europe. <i>Critical Care</i> , 2021, 25, 344.	2.5	21
320	Computational prediction of the molecular mechanism of statin group of drugs against SARS-CoV-2 pathogenesis. <i>Scientific Reports</i> , 2022, 12, 6241.	1.6	12
321	The Fungal Gut Microbiome Exhibits Reduced Diversity and Increased Relative Abundance of Ascomycota in Severe COVID-19 Illness and Distinct Interconnected Communities in SARS-CoV-2 Positive Patients. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 848650.	1.8	9
322	The Global Impact of COVID-19 on Solid Organ Transplantation: Two Years Into a Pandemic. <i>Transplantation</i> , 2022, 106, 1312-1329.	0.5	44
323	Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity had no antiviral effects but moderately reduced lung inflammation. <i>PLoS Pathogens</i> , 2022, 18, e1009925.	2.1	8

#	ARTICLE	IF	CITATIONS
324	Timing of Initiation of Methylprednisolone Pulse Therapy in Patients with COVID-19. <i>Covid</i> , 2022, 2, 532-539.	0.7	0
325	JAK inhibitors and COVID-19. , 2022, 10, e002838.		34
326	A Systematic Review Assessing the Underrepresentation of Cancer Patients in COVID-19 Trials. <i>Acta Haematologica</i> , 2022, 145, 235-243.	0.7	1
327	Usage of compromised lung volume in monitoring steroid therapy on severe COVID-19. <i>Respiratory Research</i> , 2022, 23, 105.	1.4	1
328	Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials. <i>Value in Health</i> , 2022, , .	0.1	5
329	Heart Failure Relapses in Response to Acute Stresses – Role of Immunological and Inflammatory Pathways. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 809935.	1.1	3
330	Metabolomic Profiling of Plasma Reveals Differential Disease Severity Markers in COVID-19 Patients. <i>Frontiers in Microbiology</i> , 2022, 13, 844283.	1.5	15
331	SARS-CoV-2 infection in chronic kidney disease patients with pre-existing dialysis: description across different pandemic intervals and effect on disease course (mortality). <i>Infection</i> , 2023, 51, 71-81.	2.3	1
332	Patients with severe COVID-19 do not have elevated autoantibodies against common diagnostic autoantigens. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 1116-1123.	1.4	3
333	Etiotropic therapy of the new coronavirus infection: expectations and realities at the beginning of 2022. Part 1. <i>Russian Family Doctor</i> , 2022, 26, 7-14.	0.1	0
334	Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). <i>Leukemia</i> , 2022, 36, 1467-1480.	3.3	63
335	Steroid therapy and antiviral treatment in SARSCoV-2 pneumonia: clinical contexts and indications. <i>Revista Espanola De Quimioterapia</i> , 2022, 35, 54-58.	0.5	1
336	HDAC Inhibition as Potential Therapeutic Strategy to Restore the Deregulated Immune Response in Severe COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 841716.	2.2	15
337	An anti-SARS-CoV-2 metabolite is reduced in diabetes. <i>Nature Metabolism</i> , 2022, 4, 501-502.	5.1	1
338	Checking for update – living systematic reviews and clinical practice guidelines in the <i>BJD</i>. <i>British Journal of Dermatology</i> , 2022, 186, 761-762.	1.4	1
339	Outpatient treatment options to address the SARS-CoV-2 variant Omicron. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 1129-1133.	2.0	8
340	Epidemiology of COVID-19 in Tehran, Iran: A Cohort Study of Clinical Profile, Risk Factors, and Outcomes. <i>BioMed Research International</i> , 2022, 2022, 1-17.	0.9	10
341	Efficacy of Colchicine in the Treatment of COVID-19 Patients: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 2615.	1.0	14

#	ARTICLE	IF	CITATIONS
342	Covid-19: Stockpiling antivirals risks repeating Tamiflu mistakes, experts warn. <i>BMJ, The</i> , 2022, 377, o1053.	3.0	1
343	Immune-based Therapeutic Approaches in COVID-19. <i>Biomedicine and Pharmacotherapy</i> , 2022, , 113107.	2.5	4
344	Molnupiravir might be dangerous without clarification of its indications. <i>BMJ, The</i> , 2022, 377, o1030.	3.0	5
346	Management of Hematologic Malignancies in the Era of COVID-19 Pandemic: Pathogenetic Mechanisms, Impact of Obesity, Perspectives, and Challenges. <i>Cancers</i> , 2022, 14, 2494.	1.7	7
347	Challenges in addressing inequity in access to COVID-19 diagnostics, therapeutics and vaccines in Africa. <i>South African Journal of Science</i> , 2022, 118, .	0.3	1
349	Corticosteroids and superinfections in COVID-19 patients on invasive mechanical ventilation. <i>Journal of Infection</i> , 2022, 85, 57-63.	1.7	29
350	Mortality in SARS-CoV-2 Hospitalized Patients Treated with Remdesivir: A Nationwide, Registry-Based Study in Italy. <i>Viruses</i> , 2022, 14, 1197.	1.5	8
351	Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1203-1210.	2.8	50
352	Prognostic Factors Associated With Mortality of Patients With COVID-19 Requiring Ventilator Management: A Retrospective Cohort Study. <i>Cureus</i> , 2022, , .	0.2	1
353	Evolving outcomes of extracorporeal membrane oxygenation during the first 2Âyears of the COVID-19 pandemic: a systematic review and meta-analysis. <i>Critical Care</i> , 2022, 26, .	2.5	34
354	Construct Validity and Responsiveness of the COVID-19 Yorkshire Rehabilitation Scale (C19-YRS) in a Cohort of Italian Hospitalized COVID-19 Patients. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 6696.	1.2	11
355	Covid-19, an unfinished story. <i>Presse Medicale</i> , 2022, 51, 104131.	0.8	8
356	Baricitinib as the treatment of choice for hospitalised individuals with COVID-19. <i>EclinicalMedicine</i> , 2022, 49, 101493.	3.2	5
357	SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	20
358	How frequently should "living" guidelines be updated? Insights from the Australian Living Stroke Guidelines. <i>Health Research Policy and Systems</i> , 2022, 20, .	1.1	5
359	The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19. <i>Vaccines</i> , 2022, 10, 951.	2.1	8
360	Parenteral Vitamin C in Patients with Severe Infection: A Systematic Review. , 2022, 1, .		20
361	Remdesivir for the treatment of patients hospitalized with COVID-19 receiving supplemental oxygen: a targeted literature review and meta-analysis. <i>Scientific Reports</i> , 2022, 12, .	1.6	21

#	ARTICLE	IF	CITATIONS
363	Chasing the Ghost: Hyperinflammation Does Not Cause Sepsis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
364	Changes in dispensing of medicines proposed for re-purposing in the first year of the COVID-19 pandemic in Australia. <i>PLoS ONE</i> , 2022, 17, e0269482.	1.1	5
365	Janus kinase inhibitors for the treatment of COVID-19. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	22
366	The role of natural products from medicinal plants against COVID-19: traditional medicine practice in Tanzania. <i>Heliyon</i> , 2022, 8, e09739.	1.4	9
367	Ivermectin for preventing and treating COVID-19. <i>The Cochrane Library</i> , 2024, 2024, .	1.5	19
368	Long-COVID in children and adolescents: a systematic review and meta-analyses. <i>Scientific Reports</i> , 2022, 12, .	1.6	203
369	A Multi-Center, Open-Label, Randomized Controlled Trial to Evaluate the Efficacy of Convalescent Plasma Therapy for Coronavirus Disease 2019: A Trial Protocol (COVIPLA-RCT). <i>Life</i> , 2022, 12, 856.	1.1	4
370	COVID-19, haemophagocytic lymphohistiocytosis, and infection-induced cytokine storm syndromes. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 937-938.	4.6	4
371	Clinical Characteristics of COVID-19: Use of Steroids in Mostly Unvaccinated COVID-19 Patients Before the Omicron Variant. <i>Journal of Korean Medical Science</i> , 2022, 37, .	1.1	3
372	Apprising the need for a living guideline approach in the COVID-19 era. <i>Journal of Anaesthesiology Clinical Pharmacology</i> , 2022, 38, 143.	0.2	0
373	Immunomodulatory therapy in dengue: need for clinical trials and evidence base. <i>Archives of Disease in Childhood</i> , 0, , archdischild-2022-324100.	1.0	1
374	Perspectives on the production, and use, of rapid evidence in decision making during the COVID-19 pandemic: a qualitative study. <i>BMJ Evidence-Based Medicine</i> , 2023, 28, 48-57.	1.7	3
375	The Relationship between COVID-19 and Hypothalamicâ€Pituitaryâ€Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excessâ€The CAPISCO International Expert Panel. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7326.	1.8	30
376	Participantsâ€™ informed consent in adaptive, platform drug trials in hospitalized COVID-19 patients: Not all approaches are ethically acceptable. <i>European Journal of Internal Medicine</i> , 2022, , .	1.0	6
377	Utility of hematological and inflammatory biomarkers in predicting recovery in critical Covid-19 patients: Our experience in the largest Covid-19 treating center in Lebanon. <i>PLoS ONE</i> , 2022, 17, e0271393.	1.1	0
378	Autophagy in health and disease: From molecular mechanisms to therapeutic target. <i>MedComm</i> , 2022, 3, .	3.1	30
379	The Relationship Between Pediatric Gut Microbiota and SARS-CoV-2 Infection. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	29
380	Role of Traditional Chinese Medicine in Treating Severe or Critical COVID-19: A Systematic Review of Randomized Controlled Trials and Observational Studies. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7

#	ARTICLE	IF	CITATIONS
382	Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1279.	4.6	41
383	Co-Administration of Remdesivir and Azithromycin May Protect against Intensive Care Unit Admission in COVID-19 Pneumonia Requiring Hospitalization: A Real-Life Observational Study. <i>Antibiotics</i> , 2022, 11, 941.	1.5	4
384	Self-reported side effects of the Oxford AstraZeneca COVID-19 vaccine among healthcare workers in Ethiopia, Africa: A cross-sectional study. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	12
385	Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis. <i>PLoS ONE</i> , 2022, 17, e0270668.	1.1	16
386	A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2022, 2022, 1-8.	0.7	2
387	The hunt for drugs for mild COVID: scientists seek to treat those at lower risk. <i>Nature</i> , 0, , .	13.7	4
388	A Framework for the Development of Living Practice Guidelines in Health Care. <i>Annals of Internal Medicine</i> , 2022, 175, 1154-1160.	2.0	34
389	In-hospital mortality in SARS-CoV-2 stratified by the use of corticosteroid. <i>Annals of Medicine and Surgery</i> , 2022, 80, .	0.5	1
390	JAK inhibition as a new treatment strategy for patients with COVID-19. <i>Biochemical Pharmacology</i> , 2022, 202, 115162.	2.0	10
391	Synthesis, spectral characterization, crystal structure and computational investigation of 2-formyl-6-methoxy-3-carboxy quinoline as potential SARS-CoV inhibitor. <i>Journal of Physics and Chemistry of Solids</i> , 2022, 170, 110886.	1.9	1
392	Systematic review and meta-analysis of ivermectin for treatment of COVID-19: evidence beyond the hype. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	20
393	Answering Ireland's call: pathology during the COVID-19 pandemic. <i>Journal of Clinical Pathology</i> , 2022, 75, 721-723.	1.0	0
394	Efficacy and safety of vitamin D supplementation in hospitalized COVID-19 pediatric patients: A randomized controlled trial. <i>Frontiers in Pediatrics</i> , 0, 10, .	0.9	13
395	Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	96
396	Definitions matter: Heterogeneity of COVID-19 disease severity criteria and incomplete reporting compromise meta-analysis. <i>PLOS Global Public Health</i> , 2022, 2, e0000561.	0.5	10
397	Critical patients COVID-19 has changed the management and outcomes in the ICU after 1 year of the pandemic? A multicenter, prospective, observational study. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2022, , .	0.2	0
398	Long-term functioning status of COVID-19 survivors: a prospective observational evaluation of a cohort of patients surviving hospitalisation. <i>BMJ Open</i> , 2022, 12, e057246.	0.8	12
399	Autoimmunity, cancer and COVID-19 abnormally activate wound healing pathways: critical role of inflammation. <i>Histochemistry and Cell Biology</i> , 2022, 158, 415-434.	0.8	8

#	ARTICLE	IF	CITATIONS
400	COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature. <i>Pathogens</i> , 2022, 11, 816.	1.2	13
401	Efficacy of Covexir® ( <i>Ferula foetida</i> oleo-gum) treatment in symptomatic improvement of patients with mild to moderate COVID-19: A randomized, double-blind, placebo-controlled trial. <i>Phytotherapy Research</i> , 2022, 36, 4504-4515.	2.8	6
402	Assessing the proportion of the Danish population at risk of clinically significant drug-drug interactions with new oral antivirals for early treatment of COVID-19. <i>International Journal of Infectious Diseases</i> , 2022, 122, 599-601.	1.5	8
403	COVID-19 and Adult Acute Leukemia: Our Knowledge in Progress. <i>Cancers</i> , 2022, 14, 3711.	1.7	6
404	Institutional, therapeutic, and individual factors associated with 30-day mortality after COVID-19 diagnosis in Canadian long-term care facilities. <i>Journal of the American Geriatrics Society</i> , 2022, 70, 3210-3220.	1.3	7
405	Applying Lessons Learned From COVID-19 Therapeutic Trials to Improve Future ALI/ARDS Trials. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	6
406	Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2023, 76, e116-e125.	2.9	13
407	Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-analysis. <i>Cmaj</i> , 2022, 194, E969-E980.	0.9	37
410	Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2693-2700.	1.3	41
411	Innate immune responses to three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
412	Persistent T cell exhaustion in relation to prolonged pulmonary pathology and death after severe COVID-19: Results from two Norwegian cohort studies. <i>Journal of Internal Medicine</i> , 2022, 292, 816-828.	2.7	4
413	COVID-19 pandemic: A multidisciplinary perspective on the pathogenesis of a novel coronavirus from infection, immunity and pathological responses. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
414	Comparative risk assessment of COVID-19 associated mucormycosis and aspergillosis: A systematic review. <i>Health Science Reports</i> , 2022, 5, .	0.6	3
415	Estimating incidence of venous thromboembolism in COVID-19: Methodological considerations. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, .	1.0	3
416	Time to Stop Using Ineffective Covid-19 Drugs. <i>New England Journal of Medicine</i> , 2022, 387, 654-655.	13.9	18
417	High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	1
418	Identification of CKD, bedridden history and cancer as higher-risk comorbidities and their impact on prognosis of hospitalized Omicron patients: a multi-centre cohort study. <i>Emerging Microbes and Infections</i> , 2022, 11, 2501-2509.	3.0	9
419	Mortality predictors in a cohort of patients with COVID-19 admitted to a large tertiary hospital in the city of São Paulo, Brazil: a retrospective study. <i>Sao Paulo Medical Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
420	A UPLC-MS/MS Method for Plasma Biological Monitoring of Nirmatrelvir and Ritonavir in the Context of SARS-CoV-2 Infection and Application to a Case. <i>Journal of the American Society for Mass Spectrometry</i> , 2022, 33, 1975-1981.	1.2	7
421	Lung-function trajectories in COVID-19 survivors after discharge: A two-year longitudinal cohort study. <i>EClinicalMedicine</i> , 2022, 54, 101668.	3.2	25
422	COVID-19 vaccine acceptance and its determinants among Vietnamese teachers: a web-based cross-sectional survey. <i>AIMS Public Health</i> , 2022, 9, 606-617.	1.1	2
423	Unfolding issues of immunity against SARS-CoV-2. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 4878.	0.3	0
424	Wie hat das Coronavirus unsere sichere Welt der Selbstverständlichkeiten verändert?. , 2022, , 193-220.		0
425	Cost-effectiveness of remdesivir plus usual care versus usual care alone for hospitalized patients with COVID-19: an economic evaluation as part of the Canadian Treatments for COVID-19 (CATCO) randomized clinical trial. <i>CMAJ Open</i> , 2022, 10, E807-E817.	1.1	2
426	Perspective: repurposed Drugs for COVID-19. <i>Archives of Medical Science</i> , 2022, 18, 1378-1391.	0.4	3
427	Fluvoxamine for the treatment of COVID-19. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	4
428	Coronavirus disease 2019 subphenotypes and differential treatment response to convalescent plasma in critically ill adults: secondary analyses of a randomized clinical trial. <i>Intensive Care Medicine</i> , 2022, 48, 1525-1538.	3.9	13
429	Evaluation of the Quality of COVID-19 Guidance Documents in Anaesthesia using the Appraisal of Guidelines for Research & Evaluation II (AGREE II) Instrument. <i>British Journal of Anaesthesia</i> , 2022, , .	1.5	0
430	A practical update on the management of patients with COVID-19. <i>Clinical Medicine</i> , 2022, 22, 468-474.	0.8	2
431	Saving millions of lives but some resources squandered: emerging lessons from health research system pandemic achievements and challenges. <i>Health Research Policy and Systems</i> , 2022, 20, .	1.1	5
432	Central Retinal Vein Occlusion After Discontinuation of Rivaroxaban Therapy in a Young Patient with COVID-19 Pulmonary Embolism: A Case Report. <i>American Journal of Case Reports</i> , 0, 23, .	0.3	1
433	AMMI Canada Practice Point: Treatments for adults with COVID-19 in 2021-2022. <i>Jammi</i> , 2022, 7, 163-169.	0.3	0
434	COVID-19 Therapies for inpatients: a review and quality assessment of clinical guidelines. <i>ERJ Open Research</i> , 0, , 00236-2022.	1.1	2
435	Scars of COVID-19: A bibliometric analysis of post-COVID-19 fibrosis. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	6
436	Efficacy and safety of chinese herbal medicine for treating mild or moderate COVID-19: A systematic review and meta-analysis of randomized controlled trials and observational studies. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
437	Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	23

#	ARTICLE	IF	CITATIONS
438	Development of an In Vitro Model of SARS-CoV-Induced Acute Lung Injury for Studying New Therapeutic Approaches. <i>Antioxidants</i> , 2022, 11, 1910.	2.2	4
439	Network pharmacology and computer-aided drug design to explored potential targets of Lianhua Qingwen and Qingfei Paidu decoction for COVID-19. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
440	Guidelines for the prevention and management of children and adolescents with COVID-19. <i>European Journal of Pediatrics</i> , 2022, 181, 4019-4037.	1.3	10
441	Three out of four published systematic reviews on COVID-19 treatments were not registered and one-third of those registered were published: a meta-research study. <i>Journal of Clinical Epidemiology</i> , 2022, 152, 36-46.	2.4	7
443	Drug genetic associations with COVID-19 manifestations: a data mining and network biology approach. <i>Pharmacogenomics Journal</i> , 2022, 22, 294-302.	0.9	2
444	Ivermectin: A Controversial Focal Point during the COVID-19 Pandemic. <i>Life</i> , 2022, 12, 1384.	1.1	6
445	Feasibility of a telephone-delivered educational intervention for knowledge transfer of COVID-19-related information to older adults in Hong Kong: a pre-post-pilot study. <i>Pilot and Feasibility Studies</i> , 2022, 8, .	0.5	0
446	Personal reflective practice can lead to change. <i>BMJ, The</i> , 0, , o2394.	3.0	0
447	Consistency of covid-19 trial preprints with published reports and impact for decision making: retrospective review. , 2022, 1, e000309.		19
448	Glucocorticoid Therapy in Respiratory Illness: Bench to Bedside. <i>Journal of Investigative Medicine</i> , 2022, 70, 1662-1680.	0.7	2
449	Predictors of clinical evolution of SARS-CoV-2 infection in hematological patients: A systematic review and meta-analysis. <i>Hematological Oncology</i> , 2023, 41, 16-25.	0.8	6
450	Nitric Oxide and its Derivatives Containing Nasal Spray and Inhalation Therapy for the Treatment of COVID-19. <i>Current Pharmaceutical Design</i> , 2022, 28, 3658-3670.	0.9	3
451	Heterogenous treatment effects of dexamethasone 12 mg vs. 6 mg in patients with COVID-19 and severe hypoxaemia - post hoc exploratory analyses of the COVID STEROID 2 trial. <i>Acta Anaesthesiologica Scandinavica</i> , 0, , .	0.7	5
452	Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7
453	Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study. <i>Vaccines</i> , 2022, 10, 1731.	2.1	41
454	Global Challenges with Oral Antivirals for COVID-19. <i>Population Health Management</i> , 2022, 25, 822-827.	0.8	1
456	Implications of an HbA1c-based Diabetes Screening on Prevalence and Effect of Dysglycemia in Patients With COVID-19. <i>Journal of Clinical Endocrinology and Metabolism</i> , 0, , .	1.8	1
458	Immune Modulation in Sepsis, ARDS, and Covid-19 - The Road Traveled and the Road Ahead. , 2022, 1, .		6



#	ARTICLE	IF	CITATIONS
459	Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England. <i>JAMA Network Open</i> , 2022, 5, e2238354.	2.8	43
460	Past, present and future of living systematic review: a bibliometrics analysis. <i>BMJ Global Health</i> , 2022, 7, e009378.	2.0	8
461	A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR). <i>European Respiratory Journal</i> , 2023, 61, 2101870.	3.1	22
463	How pragmatic are randomized trials of remdesivir and favipiravir for in-hospital treatment of COVID-19: a descriptive methodological review of trial design using the PRECIS-2 framework. <i>Journal of Clinical Epidemiology</i> , 2022, 152, 193-200.	2.4	1
465	Glucocorticoids and COVID-19. <i>Pharmacological Research</i> , 2022, 185, 106511.	3.1	11
466	Real-Time Whole Genome Sequencing to Guide Patient-Tailored Therapy of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Clinical Infectious Diseases</i> , 2023, 76, 1125-1128.	2.9	7
467	B-cell malignancies and COVID-19: a narrative review. <i>Clinical Microbiology and Infection</i> , 2023, 29, 332-337.	2.8	7
468	Association between prehospital medication and fatal outcomes in a cohort of hospitalized patients due to coronavirus disease-2019 in a referral hospital in Peru. <i>Travel Medicine and Infectious Disease</i> , 2022, 50, 102472.	1.5	1
469	Prolonged higher dose methylprednisolone versus conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS). <i>European Respiratory Journal</i> , 2023, 61, 2201514.	3.1	18
470	Effective knowledge mobilisation: creating environments for quick generation, dissemination, and use of evidence. <i>BMJ, The</i> , 0, , e070195.	3.0	1
472	Randomized Open Investigation Determining Steroid Dose in Severe COVID-19: The ROIDS-Dose Clinical Trial. <i>Cureus</i> , 2022, , .	0.2	1
473	Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform. <i>BMJ, The</i> , 0, , e071932.	3.0	42
474	Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir. <i>Viruses</i> , 2022, 14, 2540.	1.5	33
475	Early administration of tofacitinib in COVID-19 pneumonitis: An open randomised controlled trial. <i>European Journal of Clinical Investigation</i> , 2023, 53, .	1.7	3
476	Pathophysiological mechanisms of thrombosis in acute and long COVID-19. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	24
477	WHO Living Guidelines on antivirals for COVID-19 are evidence-based. <i>Lancet, The</i> , 2022, 400, 2196-2198.	6.3	6
478	Ivermectin role in the prevention of COVID-19: A systematic review and meta-analysis. <i>Journal of Clinical Pharmacology</i> , 0, , .	1.0	1
479	Antibody tests for identification of current and past infection with SARS-CoV-2. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	32

#	ARTICLE	IF	CITATIONS
480	Effects of Different Corticosteroid Doses in Elderly Unvaccinated Patients with Severe to Critical COVID-19. <i>Life</i> , 2022, 12, 1924.	1.1	1
481	Covid-19: "Grotesque inequity" that only a quarter of paxlovid courses go to poorer countries. <i>BMJ</i> , The, 0, , o2795.	3.0	3
482	Glycyrrhizic acid alters the hyperoxidative stress-induced differentiation commitment of MSCs by activating the Wnt/ $\beta$ 2-catenin pathway to prevent SONFH. <i>Food and Function</i> , 2023, 14, 946-960.	2.1	9
483	A case of amebic colitis and liver abscesses that occurred after treatment of coronavirus disease 2019 with dexamethasone. <i>IDCases</i> , 2023, 31, e01648.	0.4	1
484	Directions of development of functional missions of computer pharmaceutical knowledge bases talking into account various types of crisis situations. <i>Farmatsevtichnyi Zhurnal</i> , 2022, , 47-56.	0.1	1
485	Antiviral Activity of Interferon alfa-2b and Taurine Combination Against SARS-CoV-2 &lt;i>in vitro</i>. <i>Antibiotiki I Khimioterapiya</i> , 0, , .	0.1	0
486	Honey and <sc><i>Nigella sativa</i></sc> against <sc>COVID</sc>â€19 in Pakistan (<sc>HNSâ€COVIDâ€PK</sc>): A multicenter placeboâ€controlled randomized clinical trial. <i>Phytotherapy Research</i> , 2023, 37, 627-644.	2.8	20
487	Corticosteroid treatment in severe patients with SARS-CoV-2 and chronic HBV co-infection: a retrospective multicenter study. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	2
488	How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response?. <i>Stem Cell Reviews and Reports</i> , 0, , .	1.7	2
489	The Association of Low CD4 Expression on Monocytes and Low CD8+ T-Cell Count at Hospital Admission Predicts the Need for Mechanical Ventilation in Patients With COVID-19 Pneumonia: A Prospective Monocentric Cohort Study. , 2022, 4, e0810.		2
490	Lessons From a Negative Clinical Trial: Novel Immunological Targets for COVID-19 and Beyond*. <i>Critical Care Medicine</i> , 2023, 51, 153-156.	0.4	0
491	Risk of Malnutrition in Hospitalized COVID-19 Patients: A Systematic Review and Meta-Analysis. <i>Nutrients</i> , 2022, 14, 5267.	1.7	7
492	Ruxolitinib for severe fever with thrombocytopenia syndrome (SFTS). <i>Heliyon</i> , 2022, 8, e12462.	1.4	0
493	Supervised Machine Learning Models to Identify Early-Stage Symptoms of SARS-CoV-2. <i>Sensors</i> , 2023, 23, 40.	2.1	9
494	Respiratory Viruses and Cystic Fibrosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 196-208.	0.8	1
495	Clinical Outcomes and Survival Analysis of Remdesivir as a Treatment Option for Moderate to Severe COVID-19 Patients. <i>Covid</i> , 2022, 2, 1758-1767.	0.7	0
496	SARS-CoV-2 induces "cytokine storm" hyperinflammatory responses in RA patients through pyroptosis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
497	Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. <i>Lancet</i> , The, 2023, 401, 281-293.	6.3	174

#	ARTICLE	IF	CITATIONS
498	Regional trends in the use of steroids and favipiravir for COVID-19 treatment. <i>Journal of Infection and Public Health</i> , 2022, , .	1.9	0
499	Sequential Treatment by Antiviral Drugs Followed by Immunosuppressive Agents for COVID-19 Patients with Hematological Malignancy. <i>Infection and Drug Resistance</i> , 0, Volume 15, 7117-7124.	1.1	1
500	Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	3
502	Validation of a specialized evaluation system for COVID-19 in Japan: A retrospective, multicenter cohort study. <i>Journal of Infection and Chemotherapy</i> , 2022, , .	0.8	0
503	Influenza antivirals and their role in pandemic preparedness. <i>Antiviral Research</i> , 2023, 210, 105499.	1.9	17
504	The "myth of Hydroxychloroquine (HCQ) as post-exposure prophylaxis (PEP) for the prevention of COVID-19" is far from reality. <i>Scientific Reports</i> , 2023, 13, .	1.6	3
505	Evaluation of urinary cysteinyl leukotrienes as biomarkers of severity and putative therapeutic targets in COVID-19 patients. <i>Inflammation Research</i> , 0, , .	1.6	2
506	A Review of Coronavirus Disease 2019 in Pregnancy. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 050-065.	0.8	0
507	Multicenter Caseâ€“Control Study of COVID-19â€“Associated Mucormycosis Outbreak, India. <i>Emerging Infectious Diseases</i> , 2023, 29, 8-19.	2.0	33
508	Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY. , 2023, 2, e000276.		10
509	Clinical characteristics and clinical outcome of community clusters with SARS-CoV-2 infection. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	0
510	The evidence base for emergency use authorizations for COVIDâ€“19 treatments: A rapid review. <i>Health Science Reports</i> , 2023, 6, .	0.6	1
511	Polypharmacology of ambroxol in the treatment of COVID-19. <i>Bioscience Reports</i> , 0, , .	1.1	0
512	Methods for living guidelines: early guidance based on practical experience. Paper 1: Introduction. <i>Journal of Clinical Epidemiology</i> , 2023, 155, 84-96.	2.4	17
513	A mixed methods study exploring requests for unproven COVID therapies such as ivermectin and healthcare distrust in the rural South. <i>Preventive Medicine Reports</i> , 2023, 31, 102104.	0.8	0
514	Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir. <i>Clinical Microbiology and Infection</i> , 2023, 29, 543.e5-543.e9.	2.8	9
516	Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk Patients. <i>Viruses</i> , 2023, 15, 119.	1.5	6
518	VV116 versus Nirmatrelvirâ€“Ritonavir for Oral Treatment of Covid-19. <i>New England Journal of Medicine</i> , 2023, 388, 406-417.	13.9	97

#	ARTICLE	IF	CITATIONS
520	Exploring the Role of Immune System and Inflammatory Cytokines in SARS-CoV-2 Induced Lung Disease: A Narrative Review. <i>Biology</i> , 2023, 12, 177.	1.3	11
521	Sepsis presentation and pathophysiology. , 2023, , 489-501.		0
523	Use of Monoclonal Antibodies in Immunocompromised Patients Hospitalized with Severe COVID-19: A Retrospective Multicenter Cohort. <i>Journal of Clinical Medicine</i> , 2023, 12, 864.	1.0	4
524	Nirmatrelvirâ€“ritonavir therapy and COVIDâ€“19 vaccination improve clinical outcomes of SARSâ€“CoVâ€“2 Omicron variant infection. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	5
526	Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibodyâ€“Associated Diseases. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2023, 10, .	3.1	7
527	Treatment of patients with pericarditis with anti-inŒammatory drugs. <i>Klinicheskaia Meditsina</i> , 2023, 100, 509-519.	0.2	2
528	The Research Progress of COVID-19 Related Kidney Injury. <i>Advances in Clinical Medicine</i> , 2023, 13, 1452-1460.	0.0	0
529	The D405N Mutation in the Spike Protein of SARS-CoV-2 Omicron BA.5 Inhibits Spike/Integrins Interaction and Viral Infection of Human Lung Microvascular Endothelial Cells. <i>Viruses</i> , 2023, 15, 332.	1.5	5
530	Association between ivermectin treatment and mortality in COVID-19: A hospital-based case-control study. <i>Journal of Family Medicine and Primary Care</i> , 2023, 12, 139.	0.3	0
531	The Role of Steroids. <i>Lessons From the ICU</i> , 2023, , 265-276.	0.1	0
532	Identification of structural scaffold from interbioscreen (IBS) database to inhibit 3CLpro, PLpro, and RdRp of SARS-CoV-2 using molecular docking and dynamic simulation studies. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 13168-13179.	2.0	0
533	A lingua franca for guidelinesâ€“ or a Tower of Babel?. <i>Acta Anaesthesiologica Scandinavica</i> , 2023, 67, 840-841.	0.7	1
534	Neutralization of the new coronavirus by extracting their spikes using engineered liposomes. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2023, 50, 102674.	1.7	2
535	Insights from comparison of the clinical presentation and outcomes of patients hospitalized with COVID-19 in an Italian internal medicine ward during first and third wave. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	3
536	Conceptualizing the reporting of living systematic reviews. <i>Journal of Clinical Epidemiology</i> , 2023, 156, 113-118.	2.4	1
537	Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	16
539	Use of COVID-19 Convalescent Plasma for Treatment of Symptomatic SARS-CoV-2 Infection at a Childrenâ€“s Hospital: A Contribution to a Still Inadequate Body of Evidence. <i>Children</i> , 2023, 10, 350.	0.6	1
540	Use and effectiveness of remdesivir for the treatment of patients with covid-19 using data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS): a multicentre cohort study. <i>Infection</i> , 2023, 51, 1033-1049.	2.3	8

#	ARTICLE	IF	CITATIONS
541	Quercetin for the treatment of COVID-19 patients: A systematic review and meta-analysis. <i>Reviews in Medical Virology</i> , 2023, 33, .	3.9	12
542	Compliance with World Health Organization's COVID-19 guidelines among Iraqi health workers. <i>World Medical and Health Policy</i> , 0, , .	0.9	0
543	Insights into COVID-19-associated critical illness: a narrative review. <i>Annals of Translational Medicine</i> , 2023, 11, 220-220.	0.7	2
544	French pharmacovigilance survey of casirivimab - imdevimab monoclonal antibodies in coronavirus disease (COVID-19). <i>Therapie</i> , 2023, , .	0.6	0
545	Molnupiravir and nirmatrelvir-ritonavir reduce mortality risk during post-acute COVID-19 phase. <i>Journal of Infection</i> , 2023, , .	1.7	3
546	Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. <i>Lancet Respiratory Medicine</i> , 2023, 11, 453-464.	5.2	35
547	Could the fibromyalgia syndrome be triggered or enhanced by COVID-19?. <i>Inflammopharmacology</i> , 2023, 31, 633-651.	1.9	9
548	Pituitary and SARS CoV-2: An unremitting conundrum. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2023, 37, 101752.	2.2	6
549	CFTR Inhibitors Display In Vitro Antiviral Activity against SARS-CoV-2. <i>Cells</i> , 2023, 12, 776.	1.8	3
550	Low vitamin D levels predict outcomes of COVID-19 in patients with both severe and non-severe disease at hospitalization. <i>Endocrine</i> , 2023, 80, 669-683.	1.1	13
551	Effects of 12Âmg vs. 6Âmg dexamethasone on thromboembolism and bleeding in patients with critical COVID-19 - a post hoc analysis of the randomized, blinded COVID STEROID 2 trial. <i>Annals of Intensive Care</i> , 2023, 13, .	2.2	1
552	Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2.0 study. <i>Clinical and Experimental Medicine</i> , 2023, 23, 2275-2285.	1.9	1
553	A patient-tailored approach for corticosteroid treatment in COVID-19: still not there yet. <i>European Respiratory Journal</i> , 2023, 61, 2300270.	3.1	0
554	GRADE guidance 36: updates to GRADE's approach to addressing inconsistency. <i>Journal of Clinical Epidemiology</i> , 2023, 158, 70-83.	2.4	15
555	Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine. <i>Medicina (Lithuania)</i> , 2023, 59, 541.	0.8	1
556	Perspective from anesthesiologists on the therapy of critically ill patients with COVID-19. , 2023, 1, .		1
557	Colchicine reduces the activation of NLRP3 inflammasome in COVID-19 patients. <i>Inflammation Research</i> , 2023, 72, 895-899.	1.6	2
558	Steroid Pulse Therapy as a Treatment for Patients With COVID-19 Pneumonia at an Intensive Care Unit: A Single-Center Retrospective Observational Study. <i>Cureus</i> , 2023, , .	0.2	0

#	ARTICLE	IF	CITATIONS
559	Identification of berberine as a potential therapeutic strategy for kidney clear cell carcinoma and COVID-19 based on analysis of large-scale datasets. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
560	Changing patterns and clinical outcomes of hospitalized patients with COVID-19 severe pneumonia treated with remdesivir according to vaccination status: results from a real-world retrospective study. <i>Clinical and Experimental Medicine</i> , 2023, 23, 2749-2756.	1.9	5
561	Remdesivir for COVID-19 and acute kidney injury: disproportionality analysis of data from the U.S. Food and Drug Administration Adverse Event Reporting System. <i>International Journal of Clinical Pharmacy</i> , 2023, 45, 509-514.	1.0	6
562	Clinical application of SARS-CoV-2 antibody detection and monoclonal antibody therapies against COVID-19. <i>World Journal of Clinical Cases</i> , 0, 11, 2168-2180.	0.3	2
563	Hyperinflammation and complement in COVID-19. <i>American Journal of Hematology</i> , 2023, 98, .	2.0	10
564	Did Ghana Do Enough? A Scientometric Analysis of COVID-19 Research Output from Ghana within the African Context. <i>Diseases (Basel, Switzerland)</i> , 2023, 11, 56.	1.0	1
565	Host-Based Treatments for Severe COVID-19. <i>Current Issues in Molecular Biology</i> , 2023, 45, 3102-3121.	1.0	3
566	Data-driven analysis to understand long COVID using electronic health records from the RECOVER initiative. <i>Nature Communications</i> , 2023, 14, .	5.8	12
567	Use of Remdesivir in Patients with SARS-CoV-2 Pneumonia in a Real-Life Setting during the Second and Third COVID-19 Epidemic Waves. <i>Viruses</i> , 2023, 15, 947.	1.5	2
568	Antiviral Activity of Acetylsalicylic Acid against Bunyamwera Virus in Cell Culture. <i>Viruses</i> , 2023, 15, 948.	1.5	0
569	Investigational Use of Mesenchymal Stem/Stromal Cells and Their Secretome as Add-On Therapy in Severe Respiratory Virus Infections: Challenges and Perspectives. <i>Advances in Therapy</i> , 2023, 40, 2626-2692.	1.3	8
571	Meta-Analysis of Glucocorticoids for Covid-19 Patients Not Receiving Oxygen. , 2023, 2, .		7
572	Therapeutic strategies for COVID-19: progress and lessons learned. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 449-475.	21.5	112
573	Effect of remdesivir post-exposure prophylaxis and treatment on pathogenesis of measles in rhesus macaques. <i>Scientific Reports</i> , 2023, 13, .	1.6	2
574	Causal Bayesian machine learning to assess treatment effect heterogeneity by dexamethasone dose for patients with COVID-19 and severe hypoxemia. <i>Scientific Reports</i> , 2023, 13, .	1.6	4
604	Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9). <i>Leukemia</i> , 2023, 37, 1933-1938.	3.3	4
616	Traditional Herbal Medicines and Their Active Constituents in Combating SARS-CoV-2 Infection. , 2023, , 137-188.		0
643	Clinical course and management of COVID-19 in the era of widespread population immunity. <i>Nature Reviews Microbiology</i> , 2024, 22, 75-88.	13.6	1

#	ARTICLE	IF	CITATIONS
657	Anti-inflammatory Drugs: Glucocorticoids. , 2023, , 265-275.		0